TB/HIV
Tuberculosis/HIV Coinfection DHHS Last Updated: September 2024Australian Commentary Last Updated: July 2023 AU Comment: Timing of ART commencement in OIs Data on when to commence ART in HIV patients with an opportunistic infection (OI) are mostly derived from studies undertaken in resource-limited countries where medical care and patient follow-up may be different to Australia. In […]
Considerations for Antiretroviral Use in Patients with Coinfections
This section has information on Considerations for Antiretroviral Use in Patients with Coinfections. Please click on the below links or follow the table of contents to access the information you are looking for. TB/HIV HCV/HIV HBV/HIV
Adherence to the Continuum of Care
DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 AU Comment: Australian data on rates of virological suppression The 2024 HIV Annual Surveillance Report states there were an estimated 30, 010 people living with HIV in Australia at the end of 2023. Of those, an estimated 92% (27 650) had received an HIV diagnosis. […]
Adverse Effects of ARV Agents
Adverse Effects of Antiretroviral Agents DHHS Last Updated: May 2023Australian Commentary Last Updated: July 2023 AU Comment: Weight gain and INSTIs Several reports have identified associations between the use of integrase strand transfer inhibitors (INSTIs) and increased weight and/or body mass index (BMI). It is unclear if this is a causal relationship or is associated […]
Cost Considerations and ART
Cost Considerations and Antiretroviral Therapy DHHS Last Updated: September 2024Australian Commentary Last Updated: January 2025 AU Comment: ART access in Australia The PBS facilitates affordable access to ART, significantly mitigating out-of-pocket costs for patients with Medicare. For example, a concessional PBS co-payment caps prescription costs AUD $7.30 per script (2025). Non-concessional patients pay up to […]
Limitations to Treatment Safety & Efficacy
This section has information on Limitations to Treatment Safety & Efficacy. Please click on the below links or follow the table of contents to access the information you are looking for. Cost Considerations and ART Adverse Effects of ARV Agents Adherence to the Continuum of Care
Overview
DHHS Last Updated: September 2024 Australian Commentary Last Updated: December 2024 AU Comment: Additional PK data and resources ARVs requiring specific acidity (e.g. ATV and RPV) may also be affected by the physiological effects of oral supplementation – variable concentration-specific effects of supplementation on gastric pH and absorption of ARVs cannot be excluded as having […]
PI Drug interactions
Drug Interactions Between Protease Inhibitors and Other Drugs DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 Table 24a. Drug Interactions Between Protease Inhibitors and Other Drugs This table provides information on the known or predicted interactions between protease inhibitors (PIs) and non-antiretroviral (ARV) drugs. The term “PI” refers to atazanavir (ATV) or darunavir (DRV) […]
NNRTI interactions
Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Other Drugs DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 AU Comment: Rilpivirine (RPV) Despite there being no direct effect on RPV plasma concentration, high doses of oral supplements may modify gastric pH, thereby affecting RPV absorption – subsequent potential impact on maintenance of viral […]
NRTI interactions
Drug Interactions Between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents) DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 Table 24c. Drug Interactions Between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents) This table provides information on the known or predicted interactions between nucleoside reverse transcriptase inhibitors (NRTIs) and […]